Introduction

Pemetor 100 mg (Pemetrexed) Injection is a potent antifolate chemotherapy agent designed for the treatment of non-squamous non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma. Manufactured by Eskayef Pharmaceuticals Ltd. and supplied globally by Onco Solution, Pemetor 100 mg (Pemetrexed) Injection offers a targeted approach to cancer therapy by inhibiting key enzymes involved in DNA synthesis. With its proven efficacy and manageable safety profile, Pemetor 100 mg (Pemetrexed) Injection is a cornerstone in modern oncology protocols.

Indications

Pemetor 100 mg (Pemetrexed) Injection is indicated for:

1. Initial Treatment: Locally advanced or metastatic non-squamous NSCLC in combination with cisplatin.
2. Maintenance Therapy: Non-squamous NSCLC patients without disease progression after platinum-based first-line chemotherapy.
3. Recurrent NSCLC: As a single agent for metastatic non-squamous NSCLC after prior chemotherapy.
4. Mesothelioma: In combination with cisplatin for malignant pleural mesothelioma.

Pharmacology

Pemetor 100 mg (Pemetrexed) Injection exerts its antineoplastic effects by inhibiting multiple folate-dependent enzymes, including thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. This inhibition disrupts purine and thymidine synthesis, leading to impaired DNA replication and cell death in rapidly dividing cancer cells.

Dosage & Administration

Pemetor 100 mg (Pemetrexed) Injection is administered intravenously under the supervision of an oncology specialist.

Recommended Dosage:

• Non-Squamous NSCLC:
  • Initial Treatment: 500 mg/m² IV over 10 minutes, followed by cisplatin on Day 1 of a 21-day cycle for up to 6 cycles.
  • Maintenance Therapy: 500 mg/m² IV over 10 minutes on Day 1 of each 21-day cycle until disease progression.
  • Recurrent NSCLC: 500 mg/m² IV over 10 minutes on Day 1 of each 21-day cycle until disease progression.
• Mesothelioma:
  • 500 mg/m² IV over 10 minutes, followed by cisplatin on Day 1 of each 21-day cycle.

Premedication:

• Folic acid (400–1000 mcg daily) starting 1 week before treatment and continuing for 21 days after the last dose.
• Vitamin B12 (1000 mcg IM) 1 week before the first dose and every 9 weeks thereafter.
• Dexamethasone (4 mg twice daily) for 3 days starting the day before treatment to reduce skin toxicity.

Drug Interactions

• NSAIDs: Avoid high doses 2 days before, during, and 2 days after Pemetor 100 mg (Pemetrexed) Injection in patients with renal impairment.
• Nephrotoxic Drugs: Increased risk of toxicity with aminoglycosides, loop diuretics, and platinum compounds.
• Tubular Secretion Inhibitors: Reduced clearance with probenecid or penicillin.

Contraindications

• Hypersensitivity to pemetrexed or any component of the formulation.
• Severe renal impairment (creatinine clearance <45 mL/min).

Side Effects

Common Adverse Reactions:

• Hematologic: Myelosuppression (neutropenia, anemia, thrombocytopenia).
• Gastrointestinal: Nausea, vomiting, diarrhea, stomatitis.
• Dermatologic: Rash, erythema, pruritus.
• Renal: Increased creatinine, renal failure.

Serious Risks:

• Interstitial pneumonitis.
• Radiation recall.
• Bullous and exfoliative skin toxicity.

Pregnancy & Lactation

• Pregnancy Category D: Pemetor 100 mg (Pemetrexed) Injection may cause fetal harm. Use only if benefits outweigh risks.
• Lactation: Advise against breastfeeding during treatment and for 1 week after the final dose.

Precautions & Warnings

• Monitor CBC and renal function regularly.
• Premedicate with folic acid, vitamin B12, and dexamethasone to reduce toxicity.
• Use with caution in patients with renal or hepatic impairment.

Use in Special Populations

• Renal Impairment: Not recommended for patients with creatinine clearance <45 mL/min.
• Pediatric Use: Safety and efficacy not established.
• Geriatric Use: Higher incidences of Grade 3–4 anemia, fatigue, and neutropenia in patients ≥65 years.

Overdose Management

No specific antidote exists for Pemetor 100 mg (Pemetrexed) Injection overdose. Leucovorin may mitigate toxicity. Dialysis is not effective.

Storage Conditions

• Store at 25°C (77°F); excursions permitted to 15–30°C (59–86°F).
• Protect from light and freezing.

Manufacturing Excellence

Pemetor 100 mg (Pemetrexed) Injection is manufactured by Eskayef Pharmaceuticals Ltd., a WHO-GMP-certified company with over 30 years of expertise in oncology therapeutics. Their state-of-the-art facilities ensure:

• Rigorous quality control.
• Compliance with international standards.

Global Supply Network

Onco Solution, the global supplier of Pemetor 100 mg (Pemetrexed) Injection, guarantees:

• Reliable, temperature-controlled logistics.
• Compliance with global regulatory requirements.

Clinical Value Proposition

Pemetor 100 mg (Pemetrexed) Injection offers:

• Targeted inhibition of folate-dependent enzymes.
• Proven efficacy in NSCLC and mesothelioma.
• Enhanced safety with premedication protocols.

Conclusion

Pemetor 100 mg (Pemetrexed) Injection is a vital therapeutic option for non-squamous NSCLC and mesothelioma, combining clinical efficacy with a manageable safety profile. Backed by Eskayef Pharmaceuticals Ltd.’s manufacturing excellence and Onco Solution’s global distribution network, Pemetor 100 mg (Pemetrexed) Injection ensures reliable access to life-saving oncology care.